Nuvation Bio (NUVB) AI Stock Analysis

• Market Cap: $632.89M
• Dividend Yield: N/A
• Average Volume (3M): 5.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.07
• Revenue Growth: N/A
• EPS Growth: -551.08%
• Country: US
• Employees: 273
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -0.16
• Shares Outstanding: 339,262,970
• 10 Day Avg. Volume: 8,756,416
• 30 Day Avg. Volume: 5,544,808
• PEG Ratio: -1.88
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.31
• Enterprise Value/Market Cap: 0.50
• Enterprise Value/Revenue: 13.91
• Enterprise Value/Gross Profit: 207.18
• Enterprise Value/Ebitda: -0.14
• 1Y Price Target: $7.40
• Price Target Upside: 297.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 45 Neutral
• Price Target: ―

Nuvation Bio's stock is primarily challenged by weak financial performance, characterized by ongoing losses and negative cash flows, despite a strong equity foundation. While there is short-term momentum in the stock price, the lack of sustainable income and negative valuation metrics, such as a negative P/E ratio, weigh heavily on the overall score. The stock's speculative nature and reliance on future growth prospects contribute to its moderate overall score.

Positive Factors

Market Penetration

Nuvation expects higher market penetration than the conservative 30% assumption, mainly due to higher mPFS vs peers, CNS efficacy, and a better safety profile.

Market Position

IBTROZI could rapidly ascend to best-in-disease status relative to competitors, while other agents remain sidelined due to lack of efficacy against CNS metastases.

Regulatory Approval

The FDA granted full approval to IBTROZI (taletrectinib) for the treatment of advanced ROS1+ non-small cell lung cancer on a line-agnostic basis.

Negative Factors

Competitive Pressure

Upcoming catalyst from NUVL puts pressure on NUVB: Investors are also looking at Nuvalent's potentially pivotal data in 2Q25 in late-line ROS1+ NSCLC.

Market Dynamics

The FDA granted priority review status to taletrectinib in ROS1+ NSCLC, indicating a significant market opportunity despite a crowded space.

Nuvation Bio Business Overview & Revenue Model

Company Description

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

How the Company Makes Money

Nuvation Bio makes money primarily through the development and commercialization of its pharmaceutical products. The company generates revenue from various streams, including partnerships with other biotech and pharmaceutical companies, licensing agreements, and potential future sales of its drug candidates once they receive regulatory approval. Significant partnerships with industry players or research institutions can also provide funding and collaborative opportunities, contributing to the company's financial growth. Additionally, Nuvation Bio may engage in strategic collaborations to enhance its research and development capabilities, which can also lead to milestone payments and royalties that serve as key revenue streams.

Nuvation Bio Financial Statement Overview

Summary

Nuvation Bio faces significant financial challenges, marked by consistent net losses and negative cash flows, despite a strong equity base and low leverage. The recent revenue increase is a positive sign, yet operational and cash flow improvements are necessary for long-term sustainability. The company's financial health is currently weak, primarily due to its inability to generate positive net income and operating cash flow.

Income Statement

Nuvation Bio has struggled with profitability, exhibiting a negative net profit margin due to substantial net losses over the years. Although there was a notable revenue increase in 2024, margins remain negative, highlighting ongoing operational challenges. The absence of revenue in prior years underscores the lack of stable income streams.

Balance Sheet

The company maintains a strong equity position with a debt-to-equity ratio that indicates low leverage, which is a positive aspect. However, the persistent negative net income has affected the return on equity, which is currently unfavorable. The equity ratio is high, showing that the company is mainly financed through equity, which can be advantageous in managing financial risk.

Cash Flow

Nuvation Bio's cash flow statement reveals a lack of positive operating cash flow, with free cash flow also being negative. This signifies potential issues in cash generation from operations. The company has been relying on financing activities to support cash needs, which may not be sustainable in the long term.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
10.96M	7.87M	0.00	0.00	0.00	0.00
	Gross Profit
1.54M	795.00K	-222.00K	-484.00K	-368.00K	-103.00K
	EBIT
-206.36M	-592.63M	-99.82M	-119.73M	-93.32M	-43.55M
	EBITDA
-611.35M	-566.91M	-99.60M	-119.53M	-89.35M	-43.45M
	Net Income Common Stockholders
-606.38M	-567.94M	-75.80M	-88.66M	-79.73M	-39.50M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
461.68M	502.69M	611.21M	661.01M	765.39M	215.75M
	Total Assets
492.49M	540.63M	621.48M	672.14M	776.15M	221.79M
	Total Debt
11.41M	8.91M	4.01M	4.26M	3.06M	0.00
	Net Debt
-36.56M	-26.81M	-38.64M	-96.84M	-129.37M	-29.75M
	Total Liabilities
73.03M	76.84M	16.36M	17.07M	30.15M	6.71M
	Stockholders Equity
419.46M	463.79M	605.12M	655.08M	746.00M	215.08M
Cash Flow		Free Cash Flow
-114.85M	-130.57M	-68.07M	-96.48M	-68.47M	-36.67M
	Operating Cash Flow
-114.71M	-130.41M	-68.00M	-96.11M	-68.19M	-36.53M
	Investing Cash Flow
169.34M	122.70M	8.92M	63.46M	-454.67M	-70.32M
	Financing Cash Flow
858.00K	331.00K	628.00K	1.33M	625.53M	133.13M

Nuvation Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUVB, the sentiment is Negative. The current price of 1.86 is below the 20-day moving average (MA) of 2.24, below the 50-day MA of 2.13, and below the 200-day MA of 2.40, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 38.43 is Neutral, neither overbought nor oversold. The STOCH value of 10.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUVB.

Nuvation Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRAX	54 Neutral	$892.37M	―	-63.56%	―	270.02%	32.69%
Sector *	54 Neutral	$5.34B	3.27	-45.10%	3.30%	16.80%	0.02%
XNCR	52 Neutral	$654.06M	―	-33.48%	―	-25.88%	-29.16%
ABUS	50 Neutral	$676.09M	―	-79.02%	―	-50.69%	8.01%
BCAX	48 Neutral	$545.36M	―	34.94%	―	―	―
NUVB	45 Neutral	$632.89M	―	-119.66%	―	―	-551.08%
RCKT	40 Underperform	$315.67M	―	-60.45%	―	―	6.99%

Nuvation Bio Corporate Events

Nuvation Bio CEO Departs After Achieving Key Goals

On February 12, 2025, Dr. Jerry Wang, CEO of AnHeart Therapeutics, a subsidiary of Nuvation Bio Inc., departed the company after achieving key goals, including regulatory approvals for taletrectinib in China and the U.S., and the integration of AnHeart Therapeutics post-merger. Dr. Wang’s departure was not due to any disagreements, and his role as CEO was deemed unnecessary following these accomplishments.